Drugs / 18F-FFNP
18F-FFNP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00968409 | Jan 2007 → Jan 2011 | breast cancer | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02455453 | Apr 2015 → Jan 2019 | breast cancer | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (18)F-FFNP | “This first-in-human study was designed to evaluate the safety and dosimetry of the progesterone analog...” PMID 22331216 ↗ Feb 2012 |
| Known as | 21-(18)F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione | “This first-in-human study was designed to evaluate the safety and dosimetry of the progesterone analog...” PMID 22331216 ↗ Feb 2012 |
| Known as | F18-FFNP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00968409 ↗ |
| Known as | FFNP | “progestin analog, 21-[18F]fluorofuranylnorprogesterone (FFNP)” PMID 33531464 ↗ Feb 2021 |
| Modality | Diagnostic / imaging agent | “PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer” NCT00968409 ↗ |